文献速递乳腺癌

早期乳腺癌或导管原位癌大分割与标准分割放疗随机III期试验:DBCG HYPO

Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial.
PubMed 文献 · J Clin Oncol · 2020-09-10

结论认为中度大分割放疗未增加乳腺硬结,其他正常组织效应轻微。

要点

  • 9年局部区域复发风险两组均低(3.3% vs 3.0%),9年总生存均为93.4%。
  • 40 Gy组毛细血管扩张、色素沉着、瘢痕外观、水肿和疼痛发生率低,美容效果和患者满意度高或更优。

核心结论

  • 淋巴结阴性乳腺癌或导管原位癌患者接受中度大分割放疗(40 Gy/15次) compared with 标准分割放疗(50 Gy/25次)未导致更多乳腺硬结。
  • 其他正常组织效应轻微,40 Gy组发生率相似或更低,9年局部区域复发风险低。

研究设计与样本

  • 随机分配至50 Gy/25次(n=937)或40 Gy/15次(n=917),2009-2014年从8个中心入组,其中腺癌1608例、导管原位癌246例。
  • 主要终点为3年2-3级乳腺硬结,假设局部区域复发非劣效。

主要发现

  • 9年局部区域复发风险:50 Gy组3.3%(95%CI 2.0%-5.0%),40 Gy组3.0%(95%CI 1.9%-4.5%),风险差-0.3%(95%CI -2.3%至1.7%)。
  • 9年总生存:50 Gy组93.4%(95%CI 91.1%-95.1%),40 Gy组93.4%(95%CI 91.0%-95.2%)。
  • 全身治疗和放疗推量未增加硬结风险;毛细血管扩张、色素沉着、瘢痕外观、水肿和疼痛发生率低,美容效果和患者满意度高,40 Gy组无差异或更优。
  • 放射性心脏和肺部疾病罕见,未受分割方案影响。

临床怎么用

  • 对于>40岁接受保乳手术的淋巴结阴性乳腺癌或导管原位癌患者,可考虑使用40 Gy/15次的中度大分割放疗方案。
  • 该方案与50 Gy/25次相比未增加乳腺硬结,且其他正常组织效应相似或更低,局部区域复发风险低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Given the poor results using hypofractionated radiotherapy for early breast cancer, a dose of 50 Gy in 25 fractions (fr) has been the standard regimen used by the Danish Breast Cancer Group (DBCG) since 1982. Results from more recent trials have stimulated a renewed interest in hypofractionation, and the noninferiority DBCG HYPO trial (ClincalTrials.gov identifier: NCT00909818) was designed to determine whether a dose of 40 Gy in 15 fr does not increase the occurrence of breast induration at 3 years compared with a dose of 50 Gy in 25 fr. PATIENTS AND METHODS: One thousand eight hundred eighty-two patients > 40 years of age who underwent breast-conserving surgery for node-negative breast cancer or ductal carcinoma in situ (DCIS) were randomly assigned to radiotherapy at a dose of either 50 Gy in 25 fr or 40 Gy in 15 fr. The primary end point was 3-year grade 2-3 breast induration assuming noninferiority regarding locoregional recurrence. RESULTS: A total of 1,854 consenting patients (50 Gy, n = 937; 40 Gy, n = 917) were enrolled from 2009-2014 from eight centers. There were 1,608 patients with adenocarcinoma and 246 patients with DCIS. The 3-year rates of induration were 11.8% (95% CI, 9.7% to 14.1%) in the 50-Gy group and 9.0% (95% CI, 7.2% to 11.1%) in the 40-Gy group (risk difference, -2.7%; 95% CI, -5.6% to 0.2%; P = .07). Systemic therapies and radiotherapy boost did not increase the risk of induration. Telangiectasia, dyspigmentation, scar appearance, edema, and pain were detected at low rates, and cosmetic outcome and patient satisfaction with breast appearance were high with either no difference or better outcome in the 40-Gy cohort compared with the 50-Gy cohort. The 9-year risk of locoregional recurrence was 3.3% (95% CI, 2.0% to 5.0%) in the 50-Gy group and 3.0% (95% CI, 1.9% to 4.5%) in the 40-Gy group (risk difference, -0.3%; 95% CI, -2.3% to 1.7%). The 9-year overall survival was 93.4% (95% CI, 91.1% to 95.1%) in the 50-Gy group and 93.4% (95% CI, 91.0% to 95.2%) in the 40-Gy group. The occurrence of radiation-associated cardiac and lung disease was rare and not influenced by the fractionation regimen. CONCLUSION: Moderately hypofractionated breast irradiation of node-negative breast cancer or DCIS did not result in more breast induration compared with standard fractionated therapy. Other normal tissue effects were minimal, with similar or less frequent rates in the 40-Gy group. The 9-year locoregional recurrence risk was low.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Offersen BV, Alsner J, Nielsen HM, et al. Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. J Clin Oncol. 2020. PMID: 32910709. doi:10.1200/JCO.20.01363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。